Bizacumen Inc., Nov 2009, Pages: 166
4
Osteoporosis Therapeutics: An Evolutionary Scan 4
“A Sketch of the Present Industry Scenario” 5
Facts & Figures: The Osteoporosis
Global Industry Analysts, Inc., Jan 2011, Pages: 434
This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following major therapeutic classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab
Datamonitor, Oct 2008, Pages: 199
characteristics of osteoporosis, the fact that the majority of fractures remain undetected and the lack of nationwide screening means that osteoporosis is severely under-diagnosed.
About two-thirds of the patients
Bizacumen Inc., Nov 2009, Pages: 116
The alarming rise of osteoporosis has propelled the need for early detection of the disease. Apart from this, introduction of new drug therapies and the need for frequent tests for osteoporosis
Global Markets Direct, Sep 2011, Pages: 42
Laboratories, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Unigene Laboratories, Inc. human therapeutic division
Research Facts Ltd, May 2009, Pages: 71
Did you know?
- Joint diseases account for half of all chronic conditions in persons aged 65 and over.
- Fractures related to osteoporosis have almost doubled in number in the last decade
JZMed Inc., Feb 2010, Pages: 210
of this Chinese industry experienced significant growth slowdown in the last one year or so. The financial crisis was only one of the factors to blame. It was, in fact, the severe quality incident in supply chain
GlobalData, Oct 2011, Pages: 15
the discovery and development of DNA based tests in the areas of degenerative disc disease, spondylolithesis, scheuermann’s disease, osteoarthritis and osteoporosis. Axial Biotech also provides medical
ICON Group International, Jan 2011, Pages: 329
for osteoporosis therapeutics is not actual or historic sales. Nor is latent demand future sales. In fact, latent demand can be lower either lower or higher than actual sales if a market is inefficient (i
ICON Group International, Jan 2011, Pages: 54
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 56
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 38
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 35
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 37
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 34
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 36
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 198
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics is not actual or historic
ICON Group International, Jan 2011, Pages: 142
smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for osteoporosis therapeutics in Greater China
